the terms of the generic. Burden estimates have been updated.

DATES: Comments due within 30 days of publication. OMB must make a decision about the collection of information between 30 and 60 days after publication of this document in the Federal Register. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting “Currently under 30-day Review-Open for Public Comments” or by using the search function. You can also obtain copies of the proposed collection of information by emailing OPREinfocollection@acf.hhs.gov. Identify all requests by the title of the information collection.

SUPPLEMENTARY INFORMATION:
Description: Program monitoring is a post-award process through which ACF assesses a recipient’s programmatic performance and business management performance. Monitoring activities are necessary to ensure timely action by ACF to support grantees and protect federal interests.

Program offices use information collected under this generic clearance to monitor funding recipient activities and to provide support or take appropriate action, as needed. The information gathered is or will be used primarily for internal purposes, but aggregate data may be included in public materials such as Reports to Congress or program office documents. Following standard OMB requirements, ACF will submit a request for each individual data collection activity under this generic clearance. Each request will include the individual form(s) or instrument(s), a justification specific to the individual information collection, and any supplementary documents. OMB is requested to review requests within 10 days of submission.

Respondents: ACF funding recipients.

Annual Burden Estimates

This request will extend approval of currently approved monitoring forms. Currently approved forms and related burden can be found here: https://www.reginfo.gov/public/do/PRAList?ref_nbr=202307-0970-014.

Burden estimates for the next three years have been updated to reflect trends in use over the past three years. These are based on averages and actual individual requests will vary based on program office need.

<table>
<thead>
<tr>
<th>Instrument</th>
<th>Number of respondents (total over request period)</th>
<th>Number of responses per respondent (total over request period)</th>
<th>Avg. burden per response (in hours)</th>
<th>Total burden (in hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Program Monitoring Forms</td>
<td>1600</td>
<td>2.5</td>
<td>12</td>
<td>48,000</td>
</tr>
</tbody>
</table>

Mary B. Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2023–22382 Filed 10–6–23; 8:45 am]
BILLING CODE 4184–79–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Food and Drug Administration Information Technology Strategy; Request for Comments; Correction

[Docket No. FDA–2023–N–3636]

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA or Agency) is correcting a notice entitled “Food and Drug Administration Information Technology Strategy; Request for Comments” that appeared in the Federal Register of September 19, 2023. The document announced the availability of an information technology (IT) strategic plan entitled the “FDA Information Technology Strategy” and a request for comment on this IT Strategy. The document was published with an incorrect set of fiscal year information. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: Casi Alexander, Office of Digital Transformation, Food and Drug Administration, FDA Library, 5630 Fishers Lane, Rm. 1087, Rockville, MD 20857, 240–402–5171, email: Casi.Alexander@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In the Federal Register of September 19, 2023 (88 FR 64435), in FR Doc. 2023–20136, the following correction is made:

On page 64436, in the third column, in the second paragraph, “Fiscal Years 2024–2026” is corrected to read “Fiscal Years 2024–2027.”


Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023–22388 Filed 10–6–23; 8:45 am]
BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Revocation of Two Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of Mpox; Availability

[FR Doc. 2023–22388 Filed 10–6–23; 8:45 am]
BILLING CODE 4184–79–P

SUMMARY: The Food and Drug Administration (FDA) is announcing the revocations of the Emergency Use Authorizations (EUAs) (the Authorizations) issued to Life Technologies Corp. (a part of Thermo Fisher Scientific Inc.), for the TaqPath Monkeypox/Orthopox Virus DNA Kit, and Becton, Dickinson and Co., for the VIAASURE Monkeypox virus Real Time PCR Reagents for BD MAX System. FDA revoked these Authorizations under the Federal Food, Drug, and Cosmetic Act (FD&C Act) as requested by these Authorization holders. The revocations, which include an explanation of the reasons for each revocation, are reprinted in this document.

DATES: The Authorization for the Life Technologies Corp. (a part of Thermo
Fisher Scientific Inc.)'s, TaqPath Monkeypox/Orthopox Virus DNA Kit is revoked as of April 18, 2023. The Authorization for the Becton, Dickinson and Co.'s, VIASURE Monkeypox virus Real Time PCR Reagents for BD MAX System is revoked as of May 24, 2023.

**ADDRESSES:** Submit written requests for a single copy of the revocations to the Office of Policy, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5431, Silver Spring, MD 20993–0002. Send one self-addressed adhesive label to assist that office in processing your request or include a Fax number to which the revocations may be sent. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the revocations.

**FOR FURTHER INFORMATION CONTACT:** Kim Sapsford-Medintz, Office of Product Evaluation and Quality, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 3216, Silver Spring, MD 20993–0002, 301–796–0311 (this is not a toll-free number).

**SUPPLEMENTARY INFORMATION:**

### I. Background

Section 564 of the FD&C Act (21 U.S.C. 360bbb–3) as amended by the Project BioShield Act of 2004 (Pub. L. 108–276) and the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (Pub. L. 113–5) allows FDA to strengthen the public health protections against biological, chemical, radiological, or nuclear agent or agents. Among other things, section 564 of the FD&C Act allows FDA to authorize the use of an unapproved medical product or an unapproved use of an approved medical product in certain situations. On December 13, 2022, FDA issued the Authorization to Life Technologies Corp. (a part of Thermo Fisher Scientific Inc.) for the TaqPath Monkeypox/Orthopox Virus DNA Kit, subject to the terms of the Authorization. Notice of the issuance of this Authorization was published in the [Federal Register](https://www.regulations.gov/) on January 11, 2023 (88 FR 1587), as required by section 564(h)(1) of the FD&C Act. On December 23, 2022, FDA issued the Authorization to Becton, Dickinson and Co. for the VIASURE Monkeypox virus Real Time PCR Reagents for BD MAX System subject to the terms of the Authorization. Notice of the issuance of this Authorization was published in the [Federal Register](https://www.regulations.gov/) on January 31, 2023 (88 FR 6262), as required by section 564(h)(1) of the FD&C Act. Subsequent updates to the Authorizations were made available on FDA’s website. The authorization of a device for emergency use under section 564 of the FD&C Act may, pursuant to section 564(g)(2) of the FD&C Act, be revoked when the criteria under section 564(c) of the FD&C Act for issuance of such authorization are no longer met (section 564(g)(2)(B) of the FD&C Act), or other circumstances make such revocation appropriate to protect the public health or safety (section 564(g)(2)(C) of the FD&C Act).

### II. Authorizations Revocation Request

In a request received by FDA on April 13, 2023, Life Technologies Corp. (a part of Thermo Fisher Scientific Inc.), requested the revocation of, and on April 18, 2023, FDA revoked, the Authorization for the Life Technologies Corp. (a part of Thermo Fisher Scientific Inc. )’s TaqPath Monkeypox/Orthopox Virus DNA Kit. Because Life Technologies Corp. (a part of Thermo Fisher Scientific Inc.), notified FDA that it is not commercially supporting the TaqPath Monkeypox/Orthopox Virus DNA Kit and no kit reagents were distributed in the United States and requested FDA revoke the Life Technologies Corp. (a part of Thermo Fisher Scientific Inc.)’s TaqPath Monkeypox/Orthopox Virus DNA Kit, FDA has determined that it is appropriate to revoke the public health or safety to revoke this Authorization.

In a request received by FDA on May 22, 2023, Becton, Dickinson and Co., requested the withdrawal of, and on May 24, 2023, FDA revoked, the Authorization for the Becton, Dickinson and Co.’s VIASURE Monkeypox virus Real Time PCR Reagents for BD MAX System. Because Becton, Dickinson and Co., notified FDA that it is not commercially manufacturing the VIASURE Monkeypox virus Real Time PCR Reagents for BD MAX System and no reagents were distributed in the United States and requested FDA revoke the Becton, Dickinson and Co.’s VIASURE Monkeypox virus Real Time PCR Reagents for BD MAX System, FDA has determined that it is appropriate to protect the public health or safety to revoke this Authorization.

### III. Electronic Access

An electronic version of this document and the full text of the revocations are available on the internet at [https://www.regulations.gov/](https://www.regulations.gov/).

### IV. The Revocations

Having concluded that the criteria for revocation of the Authorization under section 564(g)(2)(C) of the FD&C Act are met, FDA has revoked the EUA of Life Technologies Corp. (a part of Thermo Fisher Scientific Inc. )’s TaqPath Monkeypox/Orthopox Virus DNA Kit, and Becton, Dickinson and Co.’s VIASURE Monkeypox virus Real Time PCR Reagents for BD MAX System. The revocations in their entirety follow and provide an explanation of the reasons for revocations, as required by section 564(h)(1) of the FD&C Act.
April 18, 2023

Stacey Moltchanoff
Regulatory Affairs Manager
Life Technologies Corporation (a part of Thermo Fisher Scientific Inc.)
5781 Van Allen Way
Carlsbad, CA 92008

Re: Revocation of EUA220461

Dear Stacey Moltchanoff:

This letter is in response to the request from Life Technologies Corporation (a part of Thermo Fisher Scientific Inc.), in a letter received April 13, 2023, that the U.S. Food and Drug Administration (FDA) revoke the EUA for TaqPath Monkeypox/Orthopox Virus DNA Kit issued on December 13, 2022. Thermo Fisher Scientific Inc. has decided not to commercially support the EUA product and requested that the EUA be revoked. FDA understands that, as of the date of this letter, no TaqPath Monkeypox/Orthopox Virus DNA Kit reagents were distributed in the United States.

The authorization of a device for emergency use under section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360bbb-3) may, pursuant to section 564(g)(2) of the Act, be revoked when circumstances make such revocation appropriate to protect the public health or safety (section 564(g)(2)(C) of the Act). Because Thermo Fisher Scientific Inc. has requested that FDA revoke the EUA for the TaqPath Monkeypox/Orthopox Virus DNA Kit, FDA has determined that it is appropriate, to protect the public health or safety, to revoke this authorization. Accordingly, FDA hereby revokes EUA220461 for the TaqPath Monkeypox/Orthopox Virus DNA Kit, pursuant to section 564(g)(2)(C) of the Act. As of the date of this letter, the TaqPath Monkeypox/Orthopox Virus DNA Kit is no longer authorized for emergency use by FDA.

Notice of this revocation will be published in the Federal Register, pursuant to section 564(h)(1) of the Act.

Sincerely,

/s/

Jeffrey E. Shuren, M.D., J.D.
Director
Center for Devices and Radiological Health
Food and Drug Administration
May 24, 2023

Melissa Barhoover, Ph.D., RAC
Senior Regulatory Affairs Manager
Becton, Dickinson and Company
7 Lovetoe Circle,
Sparks, MD 21152-0999

Re: Revocation of EUA220453

Dear Dr. Barhoover:

This letter is in response to the request from Becton, Dickinson and Company ("BD"), in a letter received May 22, 2023, that the U.S. Food and Drug Administration (FDA) withdraw the EUA for the VIASURE Monkeypox virus Real Time PCR Reagents for BD MAX System issued on December 23, 2022. BD has decided not to manufacture or sell these kits moving forward and requested that the EUA be withdrawn. FDA understands that, as of the date of this letter, no VIASURE Monkeypox virus Real Time PCR Reagents for BD MAX System reagents were distributed in the United States.

The authorization of a device for emergency use under section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360bbb-3) may, pursuant to section 564(g)(2) of the Act, be revoked when circumstances make such revocation appropriate to protect the public health or safety (section 564(g)(2)(C) of the Act). Because BD has requested that FDA withdraw the EUA for the VIASURE Monkeypox virus Real Time PCR Reagents for BD MAX System, FDA has determined that it is appropriate, to protect the public health or safety, to revoke this authorization. Accordingly, FDA hereby revokes EUA220453 for the VIASURE Monkeypox virus Real Time PCR Reagents for BD MAX System, pursuant to section 564(g)(2)(C) of the Act. As of the date of this letter, the VIASURE Monkeypox virus Real Time PCR Reagents for BD MAX System is no longer authorized for emergency use by FDA.

Notice of this revocation will be published in the Federal Register, pursuant to section 564(h)(1) of the Act.

Sincerely,

//s//

Jeffrey E. Shuren, M.D., J.D.
Director
Center for Devices and Radiological Health
Food and Drug Administration

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting:

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Implementing Comprehensive HIV Services in Syringe Service Program Settings.

Date: November 17, 2023.
Time: 12:00 to 2:00 p.m.